Publicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (15)

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

2019

  1. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort

    Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 55-64

  2. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain

    PLoS ONE, Vol. 14, Núm. 11

2017

  1. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort

    Journal of Viral Hepatitis, Vol. 24, Núm. 4, pp. 304-311

  2. Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study

    World Journal of Gastroenterology, Vol. 23, Núm. 41, pp. 7459-7469

2016

  1. Erratum: High-resolution hepatitis c virus subtyping using ns5b deep sequencing and phylogeny, an alternative to current methods (Journal of Clinical Microbiology (2015) 53:1 (219-226))

    Journal of Clinical Microbiology

2015

  1. Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection

    Genes and Immunity, Vol. 16, Núm. 5, pp. 297-300

  2. High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods

    Journal of Clinical Microbiology, Vol. 53, Núm. 1, pp. 219-226

  3. Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153

2013

  1. Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy

    Genes and Immunity, Vol. 14, Núm. 5, pp. 317-324

2011

  1. Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C

    Clinical Pharmacology and Therapeutics, Vol. 90, Núm. 5, pp. 712-721

  2. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin

    American Journal of Gastroenterology, Vol. 106, Núm. 7, pp. 1246-1254

2009

  1. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin

    Hepatology, Vol. 50, Núm. 6, pp. 1702-1708

2006

  1. Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: Role of HBV X protein

    American Journal of Pathology, Vol. 169, Núm. 4, pp. 1215-1222

2003

  1. Comités éticos de investigación clínica y «dictamen único» de los ensayos clínicos multicéntricos

    Medicina Clinica, Vol. 120, Núm. 5, pp. 180-188